Men's Health News

RSS

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Rutgers University receives NIH grant to increase reliability of prostate cancer imaging

The National Institutes of Health has awarded a $3.3 million grant to a research team that includes Rutgers University to increase the reliability of imaging prostate cancer.

11 Oct 2010

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.

11 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. David Penson, M.D., M.P.H., professor of Urologic Surgery, will serve as Principal Investigator for the Comparative Effectiveness Analysis of Surgery and Radiation study on prostate cancer.

8 Oct 2010

New imaging technique may help in early detection of prostate cancer

Prostate cancer -- the most common cancer afflicting American men -- may be effectively diagnosed at an early stage without ionizing radiation, using a non-invasive imaging technique known as contrast-enhanced ultrasound (CEUS), according to a report announced late last week at the 25th Annual Advances in Contrast Ultrasound - ICUS Bubble Conference in Chicago.

8 Oct 2010

Prostate cancer updates

Scientists have found that genetic variations for an enzyme involved in cell energy metabolism may increase the risk of prostate cancer. This variation in genes may impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate cells' responses to hormones and other signals, according to the U.S. National Institute of Child Health and Human Development researchers and colleagues.

8 Oct 2010

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

At the annual meeting of the North-Central American Urological Association, Mark Stovsky, MD, Case Western Reserve University School of Medicine Case Medical Center, and principal investigator, presented positive data combining the AnalizaDx SIA technology with the Nanosphere Verisens ultra-sensitive PSA assay.

7 Oct 2010

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2010

Urovalve reports promising early results from Surinate Bladder Management System multi-site clinical study

Urovalve, a medical device company focused on creating superior products for urinary flow and control, reported today that early results are promising in a multi-site clinical study of the Company's Surinate® Bladder Management System. The Surinate® Bladder Management System is designed to improve the quality of life and health of men who suffer from acute or chronic urinary retention, an inability to empty the bladder.

6 Oct 2010

Low level of testosterone increases risk for Alzheimer's disease

Low levels of the male sex hormone, testosterone, in older men is associated with the onset of Alzheimer's disease, according to research by a team that includes a Saint Louis University scientist.

6 Oct 2010

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced the publication of new research in the Canadian Urological Association Journal (CUAJ) showing that large-scale deletions in mitochondrial DNA (mtDNA) can indicate cellular changes that are associated with the development of cancer.

5 Oct 2010

Public hospitals in two Australian states acquire GreenLight HPS laser consoles for BPH treatment

American Medical Systems, a leading provider of world-class devices and therapies for male and female pelvic health, today announced that eight GreenLight HPS® laser consoles have been acquired for public hospitals in the Australian states of Victoria and Queensland. The laser technology will treat patients with Benign Prostatic Hyperplasia (BPH), a non cancerous enlargement of the prostate experienced by 50 percent of men over 60.

4 Oct 2010

VIVUS announces divestiture of MUSE to Meda

VIVUS, Inc. today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED). Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

4 Oct 2010

Prostate cancer mortality rate declines among American men: AHRQ

American men with prostate cancer were 45 percent less likely to die from the disease in 2006 than they were in 1999, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

4 Oct 2010

Meda announces acquisition of global rights to erectile dysfunction product MUSE

Meda today announced the acquisition of global rights to MUSE (transurethral alprostadil), a well established product for the treatment of erectile dysfunction.

4 Oct 2010

Osteoporosis common but underestimated in old men: Study

According to the latest research osteoporosis a diseases common in women that makes bones brittle and easily breakable with age also affects men. The study suggests that this debilitating condition is often overlooked in elderly Australian men.

3 Oct 2010

Men may connect strongly to publicity campaigns about depression and suicide

A recent study revealed that men might connect strongly to publicity campaigns about depression and suicide, particularly when they have options for anonymous help. In Regensburg, Germany, a two-year intervention campaign resulted in a marked drop in male suicides.

30 Sep 2010

Men's Health News

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Rutgers University receives NIH grant to increase reliability of prostate cancer imaging

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

CDC, national leaders issue recommendations to standardize testosterone tests

Abiraterone Phase III clinical data to be presented at ESMO meeting

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

New imaging technique may help in early detection of prostate cancer

Prostate cancer updates

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Urovalve reports promising early results from Surinate Bladder Management System multi-site clinical study

Low level of testosterone increases risk for Alzheimer's disease

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Public hospitals in two Australian states acquire GreenLight HPS laser consoles for BPH treatment

VIVUS announces divestiture of MUSE to Meda

Prostate cancer mortality rate declines among American men: AHRQ

Meda announces acquisition of global rights to erectile dysfunction product MUSE

Osteoporosis common but underestimated in old men: Study

Men may connect strongly to publicity campaigns about depression and suicide

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News